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Background
Active or chronic infections may be barriers to successful
vaccines, and patients with hepatitis typically are excluded
from clinical trials testing therapeutic anticancer vaccines.
One concern is vaccines may exacerbate the underlying
infection. Hepatocellular carcinoma (HCC) often arises
in the context of viral hepatitis B (HBV) or hepatitis
C (HBC), with or without cirrhosis. HCC is seldom cured
by standard therapy because of undetectable micrometa-
static disease that is present at diagnosis. Effective non-
toxic adjunctive treatments might improve outcomes for
HCC patients who are at high risk for recurrence and
death despite surgical resection of their primary hepatoma.
Active specific immunotherapy (ASI) with autologous
dendritic cells loaded with antigens from autologous
tumor stem cell lines has been associated with promising
long-term survival in metastatic melanoma, but patients
with HBV or HCV were ineligible. Therefore a Phase
I safety trial in HCC patients with HBV and/or HIV was
warranted.
Patients and methods
Patients with previously untreated HCC who were candi-
dates for surgical resection, but not curable by resection
or liver transplant were enrolled in Shanghai, China.
Patients had a solitary lesion >5 cm in diameter, or
3 lesions with at least one > 3 cm, but no regional or
distant metastatic disease. Patients had a good perfor-
mance status, adequate blood counts and organ function.
An autologous tumor cell (TC) line was established from
the resected tumor. Irradiated autologous TC were incu-
bated with autologous dendritic cells (DC) to create a
patient-specific DC-TC product which was cryopreserved.
Approximately eight weeks after one course of trans-
arterial chemoembolization therapy (TACE), patients
received three weekly subcutaneous injections of DC-TC
suspended in 500 micrograms of sargramostim. Patients
were monitored for toxicity for 8 weeks from the start of
treatment.
Results
HCC cell lines were successfully established within
5 weeks for 15/15 patients. Eight patients taking anti-viral
medication for active HBV infection were treated (7 men,
1 woman) with ages ranging from 37 to 73 years. Each
received the planned 3 injections, which were well toler-
ated. There were no significant changes in various para-
meters, including hepatic transaminases, bilirubin,
prothrombin time, hepatitis B antigens, or viral DNA.
Conclusion
Injections of autologous DC-TC in sargramostim were not
associated with a worsening of hepatitis or other toxicities
in HBV + HCC patients. This shows sufficient safety to
justify a Phase II efficacy trial in similar patients.
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